Variable | Peritumoral lymphatic vessel density | |||||
---|---|---|---|---|---|---|
Sequential analysis | p value | Hot spot evaluation | p value | |||
Low | High | Low | High | |||
Gender | ||||||
Male Female | 35 (77.8%) 10 (22.2%) | 33 (78.6%) 09 (21.4%) | 0.929 | 32 (76.2%) 10 (23.8%) | 36 (80.0%) 09 (20.0%) | 0.667 |
Ethnic group | ||||||
White Not white | 40 (88.9%) 05 (11.1%) | 40 (95.2%) 02 (4.8%) | 0.435 | 37 (88.1%) 05 (11.9%) | 43 (95.6%) 02 (4.4%) | 0.255 |
Age | ||||||
≤ 59 years > 59 years | 22 (48.9%) 23 (51.1%) | 23 (54.8%) 19 (45.2%) | 0.584 | 21 (50.0%) 21 (50.0%) | 24 (53.3%) 21 (46.7%) | 0.756 |
Tobacco# | ||||||
No Yes | 05 (11.9%) 37 (88.1%) | 04 (10.3%) 35 (89.7%) | 1.000 | 05 (13.2%) 33 (86.8%) | 04 (9.3%) 39 (90.75) | 0.728 |
Alcohol# | ||||||
No Yes | 09 (21.4%) 33 (78.6%) | 06 (15.4%) 33 (84.6%) | 0.484 | 06 (15.8%) 32 (84.2%) | 09 (20.9%) 34 (79.1%) | 0.552 |
Tumor site | ||||||
Tongue Floor of mouth | 30 (66.7%) 15 (33.3%) | 30 (71.4%) 12 (28.6%) | 0.631 | 31 (73.8%) 11 (26.2%) | 29 (64.4%) 16 (35.6%) | 0.345 |
T stage | ||||||
T1 T2 | 12 (26.7%) 33 (73.3%) | 16 (38.1%) 26 (61.9%) | 0.254 | 12 (28.6%) 30 (71.4%) | 16 (35.6%) 29 (64.4%) | 0.486 |
Local recurrence | ||||||
No Yes | 34 (75.6%) 11 (24.4%) | 38 (90.5%) 04 (9.5%) | 0.066 | 34 (81.0%) 08 (19.0%) | 38 (84.4%) 07 (15.6%) | 0.667 |
Regional recurrence | ||||||
No Yes | 38 (84.4) 07 (15.6) | 35 (83.3%) 07 (16.7%) | 0.888 | 36 (85.7) 06 (14.3%) | 37 (82.2%) 08 (17.8%) | 0.658 |
Lymphatic embolization | ||||||
No Yes | 30 (66.7%) 15 (33.3%) | 32 (76.2%) 10 (23.8%) | 0.327 | 28 (66.7%) 14 (33.3%) | 34 (75.6%) 11 (24.4%) | 0.360 |
Blood embolization | ||||||
No Yes | 39 (86.7%) 06 (13.3%) | 36 (85.7%) 06 (14.3%) | 0.898 | 37 (88.1%) 05 (11.9%) | 38 (84.4%) 07 (15.6%) | 0.622 |
Perineural infiltration | ||||||
No Yes | 18 (40.0%) 27 (60.0%) | 25 (59,5%) 17 (40.5%) | 0.069 | 16 (38.1%) 26 (61.9%) | 27 (60.0%) 18 (40.0%) | 0.041 |
Muscular infiltration | ||||||
No Yes | 06 (13.3%) 39 (86.7%) | 10 (23.8%) 32 (76.2%) | 0.208 | 05 (11.9%) 37 (88.1%) | 11 (24.4%) 34 (75.6%) | 0.131 |
Salivary gland infiltration | ||||||
No Yes | 25 (55.6%) 20 (44.4%) | 33 (78.6%) 09 (21.4%) | 0.230 | 27 (64.3%) 15 (35.7%) | 31 (68.9%) 14 (31.1%) | 0.649 |
Lymph-nodal status# | ||||||
pN0 pN + | 30 (81.1%) 07 (18.9%) | 20 (74.1%) 07 (25.9%) | 0.503 | 26 (76.5%) 08 (23.5%) | 24 (80.0%) 06 (20.0%) | 0.733 |
Malignancy grading | ||||||
More differentiated Less differentiated | 35 (77.8%) 10 (22.2%) | 34 (81.0%) 08 (19.0%) | 0.715 | 32 (76.2%) 10 (23.8%) | 37 (82.2%) 08 (17.8%) | 0.488 |